TipRanks
Advertisement
Advertisement
Seaport Therapeutics Reaffirmed at Buy as Clinical Pipeline Advances and $50 Price Target Remains Unchanged
PremiumRatingsSeaport Therapeutics Reaffirmed at Buy as Clinical Pipeline Advances and $50 Price Target Remains Unchanged
2M ago
Seaport Therapeutics reports Q2 EPS ($1.78), consensus (66c)
Premium
The Fly
Seaport Therapeutics reports Q2 EPS ($1.78), consensus (66c)
2M ago
Seaport Therapeutics initiated with a Buy at H.C. Wainwright
Premium
The Fly
Seaport Therapeutics initiated with a Buy at H.C. Wainwright
2M ago
PremiumRatingsBuy Rating Reaffirmed on Seaport’s Advancing CNS Pipeline; $35 Price Target Maintained
4M ago
Seaport Therapeutics reports Q1 EPS ($10.34) vs. ($5.65) last year
Premium
The Fly
Seaport Therapeutics reports Q1 EPS ($10.34) vs. ($5.65) last year
4M ago
Seaport Therapeutics sees cash runway into 2029
Premium
The Fly
Seaport Therapeutics sees cash runway into 2029
4M ago
Seaport Therapeutics initiated with a Buy at Stifel
PremiumThe FlySeaport Therapeutics initiated with a Buy at Stifel
4M ago
Seaport Therapeutics initiated with an Overweight at JPMorgan
Premium
The Fly
Seaport Therapeutics initiated with an Overweight at JPMorgan
4M ago
Seaport Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Premium
The Fly
Seaport Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
4M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―